MedTrace Logo

A Phase 1a Study of PMN310 In Healthy Volunteers

NCT06105528 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2025-07-25

Study results available
· View outcomes & findings →

Summary

This first in human Phase 1a clinical trial will evaluate the safety, tolerability, and pharmacokinetics of a single IV infusion of PMN310 in healthy volunteers.

Conditions

  • Healthy Participants

Interventions

DRUG

PMN310

60-minute intravenous infusion

DRUG

Placebo

60-minute intravenous infusion

Sponsors & Collaborators

  • ProMis Neurosciences, Inc

    lead INDUSTRY

Principal Investigators

  • Alfredo Fernandez, MD · Clnical Pharmacology of Miami

  • Alexander N Prezioso, MD · Clnical Pharmacology of Miami

  • Angela Eakin, MD · Ohio Clinical Trials

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-11-18
Primary Completion
2024-07-31
Completion
2024-07-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06105528 on ClinicalTrials.gov